Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Sagimet Biosciences Inc. (SGMT) had Return on Tangible Equity of -5.45% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-13.95M |
|
-- |
|
-- |
|
$15.82M |
|
$-15.82M |
|
$1.86M |
|
$-13.95M |
|
$-13.95M |
|
$-13.95M |
|
$-13.95M |
|
$-13.95M |
|
$-13.95M |
|
$-15.82M |
|
$-15.84M |
|
53.11M |
|
53.11M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$243.99M |
|
-- |
|
$19.44M |
|
$263.43M |
|
$5.42M |
|
-- |
|
$1.86M |
|
$7.28M |
|
$256.15M |
|
$256.15M |
|
$256.15M |
|
61.78M |
|
| Cash Flow Statement Financials | |
$-19.71M |
|
$-13.80M |
|
$164.39M |
|
$35.02M |
|
$165.90M |
|
$130.88M |
|
$5.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
45.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.45% |
|
|
Return on Tangible Equity |
-5.45% |
-5.30% |
|
-5.45% |
|
$4.15 |
|
$-0.37 |
|
$-0.37 |
|